TWC
CRSP icon

TD Waterhouse Canada’s CRISPR Therapeutics CRSP Stock Holding History

TD Waterhouse Canada’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Sell
2,592
-110
-4% -$5.8K ﹤0.01% 1144
2026
Q1 		$132K Buy
2,702
+1,046
+63% +$55.2K ﹤0.01% 1132
2025
Q4 		$86.8K Sell
1,656
-59
-3% -$3.53K ﹤0.01% 1063
2025
Q3 		$113K Sell
1,715
-5
-0.3% -$287 ﹤0.01% 1001
2025
Q2 		$83.4K Buy
1,720
+600
+54% +$23.2K ﹤0.01% 1002
2025
Q1 		$37.1K Buy
1,120
+77
+7% +$3.26K ﹤0.01% 1149
2024
Q4 		$41.1K Sell
1,043
-268
-20% -$12.7K ﹤0.01% 1127
2024
Q3 		$59.7K Hold
1,311
– – ﹤0.01% 986
2024
Q2 		$70.7K Buy
1,311
+16
+1% +$925 ﹤0.01% 941
2024
Q1 		$85.3K Sell
1,295
-153
-11% -$11K ﹤0.01% 938
2023
Q4 		$90.7K Sell
1,448
-40
-3% -$2.21K ﹤0.01% 823
2023
Q3 		$65.7K Sell
1,488
-10
-0.7% -$516 ﹤0.01% 861
2023
Q2 		$87.3K Sell
1,498
-220
-13% -$12.5K ﹤0.01% 814
2023
Q1 		$80.5K Sell
1,718
-81
-5% -$3.93K ﹤0.01% 808
2022
Q4 		$76.4K Sell
1,799
-102
-5% -$5.41K ﹤0.01% 813
2022
Q3 		$128K Sell
1,901
-2,344
-55% -$170K ﹤0.01% 724
2022
Q2 		$273K Buy
4,245
+95
+2% +$5.58K ﹤0.01% 640
2022
Q1 		$277K Buy
4,150
+2,610
+169% +$164K ﹤0.01% 673
2021
Q4 		$115K Buy
+1,540
New +$135K ﹤0.01% 849

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TD Waterhouse Canada's CRSP Position: Q2 2026 in Review

TD Waterhouse Canada reduced its CRISPR Therapeutics (CRSP) stake by 4.1% in Q2 2026, selling an estimated $5.8K and leaving 2,592 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

TD Waterhouse Canada first reported a position in CRSP in Q4 2021 and has held it in 19 quarters since. The position peaked at $277K in Q1 2022. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • TD Waterhouse Canada held 2,592 shares of CRISPR Therapeutics worth $144K as of Q2 2026.
  • TD Waterhouse Canada sold 110 CRISPR Therapeutics shares in Q2 2026, an estimated $5.8K.
  • CRISPR Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1144 holding.
  • TD Waterhouse Canada first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • TD Waterhouse Canada's CRISPR Therapeutics position peaked at $277K in Q1 2022.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.